Great Point Partners
- Company typePrivate
- Founded2003
- HeadquartersGreenwich, United States
- Headcount11–50
- GTM typeB2B
- OfferingServices
What Great Point Partners does
Great Point Partners is a healthcare-focused private investment firm founded in 2003 and headquartered at 165 Mason Street, Greenwich, CT, with a transatlantic office at 14 Curzon Street, London. The firm runs two complementary strategies: (i) a series of lower middle market private equity growth buyout funds (GPP I through GPP IV) that invest in profitable healthcare companies generally with $1-$10M EBITDA in the United States, Canada, and Western Europe, and (ii) the BioMedical Value Fund (BMVF), a public life sciences equity strategy employing MDs, PhDs, and PharmDs to invest in small and mid-cap publicly traded biotechnology and life sciences companies. Across both strategies, the firm manages $1.7B in private and public equity AUM and reports 30+ industry professionals.
The investment program is organized around four healthcare verticals: biopharmaceutical services and supplies, medical device contract manufacturing, alternate site care (home care, physical therapy, urgent care), and IT-enabled healthcare businesses. Recent control acquisitions include Lyocontract (German aseptic fill/lyophilization CDMO), Eutecma (German sustainable pharma cold chain packaging), and Lenis Group (Slovenian specialty pharma distribution in Central/Eastern Europe). Portfolio activity is supported by 100+ tuck-in acquisitions across the firm's history and a dedicated eight-person sourcing team that maintains proprietary relationships, with a CEO Advisory Board and Medical Advisory Board providing operating-level guidance.
The firm earns revenue primarily through management fees on committed and invested fund capital across GPP I-IV and the BMVF, plus carried interest from successful realizations. Track record disclosed includes 37 platform acquisitions across GPP I-IV, 100+ tuck-ins averaging four per exited portfolio company, over 4x gross multiple on realized and partially realized investments as of March 2022, and 225+ directly negotiated investments through BMVF. Great Point Partners distributes via direct institutional outreach and relationship-based deal sourcing rather than intermediary channels, targeting founders and management teams of healthcare companies seeking growth capital, tuck-in acquisition support, and transatlantic expansion capability.
Great Point Partners firmographics
Firmographics- Name
- Great Point Partners
- Legal name
- Great Point Partners, LLC
- Website
- http://www.gppfunds.com
- Company type
- Private
- Founded year
- 2003
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Ownership category
- akta.pro rank
Great Point Partners industry classification
Industry- Product category
- Healthcare Private Equity Investment Management
- NAICS
- Portfolio Management and Investment Advice (523940), Funds, Trusts, and Other Financial Vehicles (525)
- SIC
- Investment Advice (6282), Investors, Nec (6799)
- akta.pro primary industry
- Healthcare & Life Sciences Growth Equity (FSANACAB)
Keywords
Where Great Point Partners is headquartered
LocationHeadquarters
- HQ city
- Greenwich
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
Great Point Partners business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Marketing or Sales, Technology or R&D, Infrastructure
Revenue model
- Private Equity Fund Management: Management fees from private equity funds (GPP I through GPP IV) plus carried interest from successful investments. Provides growth equity, growth recapitalization, and management buyout financing to healthcare companies.
- BioMedical Value Fund (BMVF): Public life sciences equity strategy investing in small and mid-capitalization publicly traded biotechnology and life sciences companies. Deep value, fundamentally focused approach with proprietary research team.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels4 records
Great Point Partners product offering
Product offeringCore offering
Great Point Partners is a healthcare-focused private investment firm that raises and manages lower middle market growth buyout private equity funds (GPP I through GPP IV) that acquire minority or majority stakes in growing, profitable healthcare companies in the US, Canada, and Western Europe. The firm also manages the BioMedical Value Fund (BMVF), a public equity strategy investing in small and mid-capitalization biotechnology and life sciences companies. Holdings span biopharmaceutical services and supplies, medical device contract manufacturing, alternate site care, and healthcare IT-enabled businesses.
Product overview
Great Point Partners is a healthcare-focused private investment firm that operates two complementary strategies: private equity growth buyout funds (GPP I-IV) investing in private healthcare companies, and the BioMedical Value Fund (BMVF) investing in publicly traded life sciences companies. The private equity funds target growing, profitable healthcare companies with management teams focused on accelerated growth, investing across biopharmaceutical services, medical device contract manufacturing, alternate site care, and IT-enabled healthcare businesses. The BMVF employs MDs, PhDs and PharmDs to identify asymmetric risk-reward opportunities in publicly traded biotech and life sciences companies.
Differentiator
Problem solved
Functional benefit
Brands
- BioMedical Value Fund (BMVF): Public life sciences equity strategy investing in small and mid-capitalization biotechnology and life sciences companies with fundamental-focused deep value investment approach.
- Great Point Partners IV (GPP IV)
- Great Point Partners III (GPP III)
Products and services
- Private Equity Funds (GPP I, II, III, IV) Lower middle market growth buyout private equity funds that make minority and majority investments in growing, profitable healthcare companies in the US, Canada, and Western Europe, targeting $1-10M EBITDA companies across biopharmaceutical services, alternate site care, medical device contract manufacturing, and healthcare IT-enabled businesses. Available to institutional limited partners (endowments, foundations, family offices, banks, pension funds).
- BioMedical Value Fund (BMVF) A public equity fund that invests in small and mid-capitalization, publicly traded biotechnology and life sciences companies, employing a deep value, fundamentally-focused investment approach. The investment team includes MDs, PhDs, and PharmDs who leverage proprietary research to identify asymmetric risk-reward opportunities within publicly traded life sciences companies. Available to institutional and accredited investors.
Quantifiable outcome
- Over 4x gross multiple on realized and partially realized investments as of March 31, 2022
- +4 more outcomes
Companies that use Great Point Partners
Customer profileNamed customers9 records
Segments5 records
Ideal customer profiles2 records
Great Point Partners technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature2 records
Great Point Partners partnerships and signals
Strategic signalPartnerships
Eleven partnerships are on record, tiered core.
- Lenis GroupcoreGreat Point Partners acquired majority stake in Lenis Group, a Slovenian-based specialty pharmaceutical commercialization and distribution partner serving Central and Eastern Europe. As part of the investment, Michel Vounatsos (former CEO of Biogen) was appointed Board Chairman. Gilead Sciences simultaneously extended its relationship with Lenis as exclusive full-service distributor across Adriatic region.
- EutecmacoreGreat Point Partners acquired majority stake in Eutecma, a German developer of sustainable, modular, and reusable temperature controlled packaging solutions for pharmaceutical cold chain shipments. The partnership supports Eutecma's global expansion and includes acquisition of proprietary reuse machine technology.
- MLM Medical LabscoreMLM Medical Labs, a GPP portfolio company, acquired Cytespace Africa Laboratories to expand global presence into South Africa and Sub-Saharan Africa. Cytespace is ISO 15189 and CAP-accredited with expertise in infectious diseases including TB, malaria, and HIV.
- American Medical StaffingcoreAmerican Medical Staffing, a GPP portfolio company, acquired Nexus Therapy to expand school professional talent solutions. GPP supports growth through strategic acquisitions and operational expertise.
- Family Resource Home CarecoreFamily Resource Home Care, a Great Point Partners portfolio company, acquired Beneficial In-Home Care, Inc., a major home care agency in Eastern Washington. GPP supports portfolio companies through strategic guidance and acquisition sourcing.
- JPA HealthcoreJPA Health, a GPP portfolio company, acquired akt health to expand global presence in European healthcare communications. JPA Health operates from offices across US, UK, and Switzerland providing integrated medical affairs, clinical development, and marketing services.
- Lyocontract GmbHcoreGreat Point Partners acquired Lyocontract GmbH, a German CDMO specializing in aseptic liquid filling and lyophilization. The acquisition helps Lyocontract expand manufacturing capabilities and global distribution during increasing demand for lyophilization services.
- JPA HealthcoreJPA Health, a GPP portfolio company, acquired BioCentric Inc., an award-winning medical communications agency supporting pharmaceutical companies with scientific platforms, clinical trial acceleration, and HCP engagement.
- Ephicacy Consulting GroupcoreEphicacy, a GPP portfolio company and biometrics CRO, acquired Advance Research Associates to enhance biostatistics and data management capabilities. ARA has supported over 700 clinical trials since 1996.
- JPA HealthcoreJPA Health, a GPP portfolio company, acquired True North Solutions to add commercial, clinical, and medical affairs capabilities with expertise in digital acceleration, predictive analytics, AI, and natural language processing.
- Family Resource Home CarecoreFamily Resource Home Care, a GPP portfolio company, acquired Companion Care Inc. to expand access to home care in the Puget Sound region. Combined operations employ over 1,700 home care professionals.
Scale indicators7 records
Recent moves7 records
Expansion highlights5 records
Great Point Partners competitors and assessment
Company assessmentBroad incumbents
- New Mountain Capital: Large healthcare-focused growth equity and buyout investor with significant AUM and a broader, multi-sector mandate. Overlaps with GPP on healthcare services and pharma services platforms but operates at a larger check size.
- Parthenon Capital Partners: Growth-oriented PE firm with a strong healthcare services franchise alongside broader B2B investments. Operates at the upper end of GPP's size band and frequently competes for healthcare services platforms.
- Kelso & Company: Established middle-market PE firm with a meaningful healthcare portfolio (e.g., acquirer of GPP's Vālenz exit). Competes in similar deal sizes and stages, providing benchmark valuation reference points.
Direct peers
- Avista Capital Partners: Healthcare-specialist private equity firm focused on growth equity, recapitalizations, and buyouts in pharma services, medical devices, and healthcare services. Comparable target deal profile and sector depth to GPP.
- Frazier Healthcare Partners: Healthcare-dedicated PE firm with growth and buyout strategies targeting profitable lower middle market healthcare companies. Direct competitor for the same $1–10M EBITDA healthcare platform deals GPP pursues.
- Excellere Partners: Lower middle market growth-oriented PE firm with a dedicated healthcare practice covering services, products, and technology. Comparable in fund size, target EBITDA range, and buy-and-build playbook.
- Health Enterprise Partners (HEP): Growth equity investor focused exclusively on healthcare services and healthcare IT companies. Directly comparable to GPP's healthcare IT-enabled businesses and alternate site care verticals.
- Linden Capital Partners: Healthcare-focused middle-market private equity firm investing in growth equity, recapitalizations, and buyouts across healthcare services, pharma services, and medical products. Closely comparable to GPP in target company profile, fund size, and sector concentration.
- Welsh, Carson, Anderson & Stowe (WCAS): Healthcare-services-heavy PE firm with a long-running franchise in lower middle market healthcare buyouts and growth equity. Highly comparable on sector specialization, fund construction, and platform-build strategy.
- WindRose Health Investors: Healthcare-focused PE firm making control and growth investments in lower middle market healthcare services, products, and technology companies. Direct competitor for the same profitable, sub-$10M EBITDA platforms GPP targets.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks5 records
Key highlights6 records
Customer concentration
Great Point Partners social profiles
Digital presenceGreat Point Partners financial estimates
Financial estimateRevenue estimate
Valuation estimate
Great Point Partners leadership team
Management profileNumber of profiles
Profiles12 records
Great Point Partners subsidiaries and ownership
Company hierarchySubsidiaries4 records
Great Point Partners funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Great Point Partners M&A and investment
M&A and investmentM&A6 records
Investments73 records
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Great Point Partners
What does Great Point Partners do?
Great Point Partners is a healthcare-focused private investment firm that raises and manages lower middle market growth buyout private equity funds (GPP I through GPP IV) that acquire minority or majority stakes in growing, profitable healthcare companies in the US, Canada, and Western Europe. The firm also manages the BioMedical Value Fund (BMVF), a public equity strategy investing in small and mid-capitalization biotechnology and life sciences companies. Holdings span biopharmaceutical services and supplies, medical device contract manufacturing, alternate site care, and healthcare IT-enabled businesses.
Is Great Point Partners a public or private company?
Great Point Partners is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was Great Point Partners founded?
Great Point Partners was founded in 2003. It employs 11 to 50 people.
Where is Great Point Partners based?
Great Point Partners is headquartered in Greenwich, United States, in the North America region.
How does Great Point Partners make money?
Two revenue lines are on record. Private Equity Fund Management is the primary driver. The others are bioMedical Value Fund (BMVF).
Who are Great Point Partners's main competitors?
Broad incumbents on record are New Mountain Capital, Parthenon Capital Partners and Kelso & Company. Direct peers are Avista Capital Partners, Frazier Healthcare Partners, Excellere Partners, Health Enterprise Partners (HEP), Linden Capital Partners, Welsh, Carson, Anderson & Stowe (WCAS) and WindRose Health Investors.
Does Great Point Partners have an API?
No public API is recorded for Great Point Partners.
What industry is Great Point Partners in?
Great Point Partners's product category is Healthcare Private Equity Investment Management. Its primary akta.pro industry code is FSANACAB, Healthcare & Life Sciences Growth Equity. Its NAICS code is 523940 and its SIC code is 6282.